The Claim

In adults with type 2 diabetes initiating injectable therapy, GLP-1 receptor agonists are associated with a 41% lower hazard of major adverse cardiovascular events (3P-MACE: death, myocardial infarction, stroke) compared to basal insulin over a median follow-up of 24 months, with a hazard ratio of 0.59 (95% CI 0.50–0.71), even after propensity score matching for age, diabetes duration, comorbidities, and concomitant medications.

Source: Cardiovascular outcomes after initiating GLP-1 receptor agonist or basal insulin for the routine treatment of type 2 diabetes: a region-wide retrospective study

What the research says

Supports is higher

Support is ahead, but a single strong opposing study can change this.

Supports
66score
Challenges
0score

These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.

Correlation
1 study reviewed
In plain English

Among adults with type 2 diabetes starting injectable treatment, those using GLP-1 receptor agonists had a lower risk of heart attack, stroke, or death over two years compared to those using basal insulin, based on statistical analysis of patient data.

See the scientific wording

In adults with type 2 diabetes initiating injectable therapy, GLP-1 receptor agonists are associated with a 41% lower hazard of major adverse cardiovascular events (3P-MACE: death, myocardial infarction, stroke) compared to basal insulin over a median follow-up of 24 months, with a hazard ratio of 0.59 (95% CI 0.50–0.71), even after propensity score matching for age, diabetes duration, comorbidities, and concomitant medications.

Why this might work

GLP-1 drugs help the body use sugar more efficiently, reduce fat buildup in blood vessels, lower blood pressure, and calm harmful inflammation, which together make heart attacks, strokes, and death less likely.

Supported mechanismbased on 1 study

What the research says

1 study

  1. Study: Cardiovascular outcomes after initiating GLP-1 receptor agonist or basal insulin for the routine treatment of type 2 diabetes: a region-wide retrospective study

    This study found that adults with type 2 diabetes who started a GLP-1 drug had far fewer heart attacks, strokes, or deaths over two years compared to those who started insulin, even when comparing people with similar health backgrounds. So, GLP-1 drugs appear safer for the heart than insulin in this group.

Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies

Fit Body Science verdict — we translate health claims into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.